TEVJF

Teva Pharmaceutical Industries Limited operates as a global pharmaceutical enterprise, engaging in the research, production, marketing, and distribution of generic medications, specialized pharmaceutical products, and biopharmaceuticals. The company's reach extends across North America, Europe, and various other international markets. Its extensive product offerings include sterile formulations, hormonal therapies, highly potent drugs, and cytotoxic compounds, available in a wide array of dosage forms. These delivery methods encompass oral tablets and capsules, injectable solutions, inhaled preparations, liquid medicines, transdermal patches, and topical ointments and creams. Additionally, Teva develops, manufactures, and commercializes active pharmaceutical ingredients. The company's primary therapeutic focus areas are the central nervous system, pain management, respiratory conditions, and oncology. Within its central nervous system portfolio, key products feature Copaxone, prescribed for relapsing multiple sclerosis; AJOVY, utilized for migraine prevention; and AUSTEDO, indicated for the treatment of tardive dyskinesia and Huntington's disease-associated chorea. In the respiratory sector, Teva provides medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all aimed at managing asthma and chronic obstructive pulmonary disease. Its oncology division includes products like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Furthermore, Teva Pharmaceutical Industries Limited maintains a collaborative agreement with MedinCell to develop and commercialize various long-acting injectable products, including a risperidone suspension designed for individuals with schizophrenia. Established in 1901, the company's corporate headquarters are located in Tel Aviv-Yafo, Israel.